

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7017596

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HARI K.K. SUBRAMANIAN	11/19/2019
CHAD FLEISCHER	11/19/2019
DENIS MALYSHEV	11/19/2019
RECEIVING PARTY DATA	
Name:	OMNIOME, INC.
Street Address:	10275 SCIENCE CENTER DRIVE
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17502526
CORRESPONDENCE DATA	
Fax Number:	(858)350-6111
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(858)350-6100
Email:	wgorman@kilpatricktownsend.com, ipefiling@kilpatricktownsend.com
Correspondent Name:	KILPATRICK TOWNSEND & STOCKTON LLP
Address Line 1:	1100 PEACHTREE STREET
Address Line 2:	SUITE 2800
Address Line 4:	ATLANTA, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	097128-1269217-032US3
NAME OF SUBMITTER:	WILLIAM H. GORMAN
SIGNATURE:	/William H. Gorman/
DATE SIGNED:	11/10/2021
Total Attachments: 3	
source=OMN-032US3_Assignment_From_Priority_097128-1269217#page1.tif	
source=OMN-032US3_Assignment_From_Priority_097128-1269217#page2.tif	
source=OMN-032US3_Assignment_From_Priority_097128-1269217#page3.tif	

ASSIGNMENT
(Patent Application)

I/We, the undersigned inventor(s) ("Assignor(s)"), have invented certain inventions and improvements disclosed in the utility (provisional or non-provisional) or design patent application(s) entitled

"METHODS AND COMPOSITIONS FOR CAPPING NUCLEIC ACIDS,"

filed with the U.S. Patent & Trademark Office on October 18, 2019


and assigned serial nos. 16/657,051.


For good and valuable consideration, the receipt and sufficiency of which I/we acknowledge, I/we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to Omniome, Inc., a corporation having a principal place of business at 10275 Science Center Drive, San Diego, California 92121 ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application(s), implicitly or explicitly;
 - (b) the above-referenced patent application(s), the right to claim priority to the above-referenced patent application(s), all applications based in whole or in part upon the above-referenced patent application(s), including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application(s);
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon me/us, as well as my/our heirs, legal representatives, and assigns.
 5. Promise and affirm that I/we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

This document shall be executable by each Assignor in parts, and the Assignment will be effective and recordable for each Assignor as of the date of that Assignor's signature.


Signature:  Date: 11/19/19
Hari Subramanian
HARI K. K. SUBRAMANIAN *hks 11/19/2019*

Signature:  Date: 11/19/2019
Chad Fleischer

Signature:  Date: 11/19/2019
Denis Malyshev

ASSIGNMENT
METHODS AND COMPOSITIONS FOR CAPPING NUCLEIC ACIDS
Docket Nos. OMNI-025A.UTL
Serial Nos. 16/657,051
Page 3 of 3

Accepted and Agreed to By: **OMNIOME, INC.**

Signature: 
Name: Catherine Lee
Title: SVP, General Counsel

Date: 01/21/2020